8-K current report · filed Mar 10, 2026

Rapport Therapeutics, Inc. (RAPP) 8-K Current Report: March 10, 2026

Item 2.02RAPP overview

Short answer

Rapport Therapeutics, Inc. (RAPP) filed an 8-K current report with the SEC on March 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 financial results announced March 10, 2026.

Rapport Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q4 and full-year 2025 financial results announced March 10, 2026
  • Full details: revenue, expenses, cash position, contained in Exhibit 99.1 press release
  • RAPP is a clinical-stage biotech; key investor focus should be on cash runway and pipeline milestones, not revenue

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Rapport Therapeutics, Inc. 8-K filings

Get the next RAPP 8-K as it lands

Follow RAPP for push alerts, or ask the research agent what this filing means.